# Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

> **NCT01422772** · PHASE1,PHASE2 · COMPLETED · sponsor: **Helixmith Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Ischemic Heart Disease

## Interventions

- **BIOLOGICAL:** VM202-0.5 mg
- **BIOLOGICAL:** VM202-1.0 mg
- **BIOLOGICAL:** VM202-2.0 mg

## Key facts

- **NCT ID:** NCT01422772
- **Lead sponsor:** Helixmith Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-02
- **Final completion:** 2014-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01422772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01422772, "Safety Study of Gene Therapy for Ischemic Heart Disease in Korea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01422772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*